OSR Holdings, Inc. (OSRH) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. OSR Holdings, Inc. is a global healthcare company formed via a business combination with OSR Holdings Co., Ltd. (Korea) on February 14, 2025. The company operates through four wholly-owned subsidiaries focusing on oral immunotherapies for cancer, design-augmented biologics for degenerative diseases, and neurovascular medical device distribution in Korea. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Sales | $1,135,517 | $1,896,789 | $881,829 | $1,792,054 |
| Gross Profit | $32,782 | $201,468 | $232,321 | $472,122 |
| Gross Margin | 2.9% | 10.6% | 26.3% | 26.3% |
| Operating Loss | $(5,229,177) | $(8,147,004) | $(3,210,108) | $(6,512,636) |
| Net Loss | $(5,225,198) | $(16,618,012) | $(2,277,488) | $(5,632,853) |
| Cash & Equivalents | $1,584,406 (as of June 30, 2025) | |||
| Total Debt (Short-term) | $4,233,366 (as of June 30, 2025) |
Note: Net loss for YTD 2025 includes approximately $8.5 million in one-time merger-related expenses.
Material Changes vs. Prior Period
- Revenue & Margins: Q2 2025 net sales increased 29% year-over-year to $1.14 million. However, gross profit collapsed by 86% to $32,782. This was driven by a 70% increase in cost of sales due to a one-time transition from a purchase-and-resale model to a consignment-based arrangement with a key supplier, resulting in inventory being sold back at cost.
- Expenses: Selling, General, and Administrative (SG&A) expenses rose 53% in Q2 and 20% YTD compared to 2024. The increase is primarily attributed to the consolidation of the SPAC entity (formerly Bellevue Life Sciences Acquisition Corp.) and significant professional fees related to the business combination.
- Other Expenses: YTD 2025 other expenses surged due to the recognition of ~$8.5 million in merger and acquisition costs.
- Liquidity: Cash and cash equivalents increased from $341,543 at year-end 2024 to $1,584,406 at June 30, 2025, aided by cash inflows from the business combination and financing activities.
Guidance, Outlook, and Risks
- Strategic Initiatives: In July 2025, the company announced a strategic roadmap to tokenize equity under Regulation D in partnership with BCM Europe AG. Additionally, a term sheet was signed to acquire Woori IO, a leader in noninvasive glucose monitoring technology, subject to due diligence and a $10/share performance condition.
- R&D Outlook: Management expects R&D expenses to range from $2.5 million to $3.0 million per quarter in the second half of 2025, potentially increasing to $5.0 million to $6.0 million per quarter.
- Capital Resources: The company has an Equity Line of Credit (ELOC) with White Lion Capital for up to $78.9 million. As of July 2025, the company raised an additional $727,887 under this facility. Management views the ELOC as a primary source for ongoing operations.
- Risks & Contingencies:
- Legal: A pending civil action by Benjamin Securities, Inc. seeks approximately $425,000 in alleged brokerage fees.
- Internal Controls: Material weaknesses in internal controls identified in Q1 2025 were remediated by June 30, 2025, and controls are now deemed effective.
- Liquidity: The company has an accumulated deficit of $30.2 million and relies on external financing (ELOC, convertible notes) to fund operations.
Investor Verification Checklist
- Merger Accounting: Verify the treatment of the $8.5 million merger expense and its impact on the YTD net loss versus recurring operational performance.
- Supplier Transition: Confirm the long-term impact of the shift to a consignment model on gross margins and revenue recognition for the RMC subsidiary.
- Debt Structure: Review the terms of the $4.2 million in short-term borrowings, including interest rates (ranging from 0% to 7%) and maturity dates (mostly within 2025).
- Convertible Instruments: Assess the dilution risk from the $1.11 million convertible notes and the ELOC facility with White Lion Capital.
- Woori IO Acquisition: Monitor the progress of the due diligence and the specific conditions required to close the acquisition of the glucose monitoring technology firm.